What is Trialjectory?
Trialjectory leverages artificial intelligence (AI) to provide patients with greater control over their cancer journey. By analyzing a global patient community's real-world data, the company aims to equip cancer patients with the insights needed to make the most informed decisions regarding their care. This patient-centric digital health platform is positioned to transform how individuals navigate complex treatment landscapes, offering a data-driven approach to personalized oncology.
How much funding has Trialjectory raised?
Trialjectory has raised a total of $22.7M across 2 funding rounds:
Angel/Seed
$2.7M
Series A
$20M
Angel/Seed (2019): $2.7M with participation from Contour Venture Partners
Series A (2022): $20M led by Contour Venture Partners, Tia Ventures, Rho Ventures, Insight Partners, and JAL Ventures
Key Investors in Trialjectory
Contour Venture Partners
Contour Venture Partners is a venture capital firm specializing in seed-stage investments, with a focus on innovative software solutions in enterprise SaaS, vertical B2B SaaS, and financial services. They act as business partners, providing advice and support to help build transformative businesses.
Tia Ventures
TIA Ventures is a seed-stage venture capital fund based in New York City that invests in exceptional B2B software companies. They emphasize a customer-obsessed approach and work closely with founding teams to amplify growth.
Rho Ventures
Rho is a venture capital firm that has been investing in innovation since 1981, focusing on companies at various stages of growth. They provide strategic value through extensive experience and aim to build sustainable businesses.
What's next for Trialjectory?
The substantial enterprise-level funding, particularly the recent Series A financing, signals Trialjectory's transition into a scaling phase. This capital infusion is expected to fuel the expansion of its AI capabilities, broaden its patient community reach, and enhance its data analytics infrastructure. The strategic backing from prominent investors suggests a focus on solidifying its market position and further developing its innovative solutions to democratize access to cutting-edge cancer therapies. Future growth will likely involve strategic partnerships and continued technological advancement in the digital health and AI oncology sectors.
See full Trialjectory company page
